KL4-surfactant (Lucinactant) protects human airway epithelium from hyperoxia

Pediatric Research

Volumn 64, Issue 2, 2008, Pages 154-158

  Zhu, Yan ^a   Miller, Thomas L ^a,b   Chidekel, Aaron ^a,b   Shaffer, Thomas H ^a,b,c  

^a NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BERACTANT; GELATINASE A; INTERLEUKIN 6; INTERLEUKIN 8; LUCINACTANT; MATRILYSIN; ANTIINFLAMMATORY AGENT; BIOLOGICAL PRODUCT; KL4 SURFACTANT; PEPTIDE;

ARTICLE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; HYPEROXIA; LUNG RESISTANCE; PRIORITY JOURNAL; RESPIRATORY EPITHELIUM; RESPIRATORY TRACT INFLAMMATION; CELL CULTURE; LUNG ALVEOLUS; METABOLISM; PATHOPHYSIOLOGY; PNEUMONIA; RESPIRATORY TRACT MUCOSA;

ANTI-INFLAMMATORY AGENTS; BIOLOGICAL PRODUCTS; CELLS, CULTURED; HUMANS; HYPEROXIA; INTERLEUKIN-6; INTERLEUKIN-8; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 7; PEPTIDES; PNEUMONIA; PULMONARY ALVEOLI; RESPIRATORY MUCOSA;

EID: 52649096955     PISSN: 00313998     EISSN: 15300447     Source Type: Journal    
DOI: 10.1203/PDR.0b013e318175dd14     Document Type: Article

References (41)

1. Jobe AH, Ikegami M, Jacobs HC, Jones SJ 1983 Surfactant pool sizes and severity of respiratory distress syndrome in prematurely delivered lambs. Am Rev Respir Dis 127:751-755
2. Falciglia HS, Johnson JR, Sullivan J, Hall CF, Miller JD, Riechmann GC, Falciglia GA 2003 Role of antioxidant nutrients and lipid peroxidation in premature infants with respiratory distress syndrome and bronchopulmonary dysplasia. Am J Perinatol 20:97-107
3. Mentro AM 2004 Vitamin A and bronchopulmonary dysplasia: research, issues, and clinical practice. Neonatal Netw J Neonatal Nurs 23:19-23
4. Loughran-Fowlds A, Oei J, Wang H, Xu H, Wimalasundera N, Egan C, Henry R, Lui K 2006 The influence of gestation and mechanical ventilation on serum clara cell secretory protein (CC10) concentrations in ventilated and nonventilated newborn infants. Pediatr Res 60:103-108
5. Splawski JB, Yamamoto K, Lipsky PE 1998 Deficient interleukin-10 production by neonatal T cells does not explain their ineffectiveness at promoting neonatal B cell differentiation. Eur J Immunol 28:4248-4256
6. Chess PR, D'Angio CT, Pryhuber GS, Maniscalco WM 2006 Pathogenesis of bronchopulmonary dysplasia. Semin Perinatol 30:171-178
7. Bhandari A, Bhandari V 2003 Pathogenesis, pathology and pathophysiology of pulmonary sequelae of bronchopulmonary dysplasia in premature infants. Front Biosci 8:e370-e380
8. Clement A 1996 Bronchopulmonary dysplasia. Rev Mal Respir 13:243-249
9. Hilgendorff A, Rawer D, Doerner M, Tutdibi E, Ebsen M, Schmidt R, Guenther A, Gortner L, Reiss I 2003 Synthetic and natural surfactant differentially modulate inflammation after meconium aspiration. Intensive Care Med 29:2247-2254
10. Meyer KC, Zimmerman JJ 2002 Inflammation and surfactant. Paediatr Respir Rev 3:308-314
11. De Dooy JJ, Mahieu LM, Van Bever HP 2001 The role of inflammation in the development of chronic lung disease in neonates. Eur J Pediatr 160:457-463
12. Bakowska J, Adamson IY 1998 Collagenase and gelatinase activities in bronchoal- veolar lavage fluids during bleomycin-induced lung injury. J Pathol 185:319-323
13. Danan C, Jarreau PH, Franco ML, Dassieu G, Grillon C, Abd Alsamad I, Lafuma C, Harf A, Delacourt C 2002 Gelatinase activities in the airways of premature infants and development of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 283:L1086-L1093
14. Corbel M, Belleguic C, Boichot E, Lagente V 2002 Involvement of gelatinases (MMP-2 and MMP-9) in the development of airway inflammation and pulmonary fibrosis. Cell Biol Toxicol 18:51-61
15. Nogee LM, Wert SE, Proffit SA, Hull WM, Whitsett JA 2000 Allelic heterogeneity in hereditary surfactant protein B (SP-B) deficiency. Am J Respir Crit Care Med 161:973-981
16. Frerking I, Gunther A, Seeger W, Pison U 2001 Pulmonary surfactant: functions, abnormalities and therapeutic options. Intensive Care Med 27:1699-1717
17. RevakSD, MerrittTA,CochraneCG, HeldtGP, AlbertsMS,AndersonDW, Kheiter A 1996 Efficacy of synthetic peptide-containing surfactant in the treatment of respiratory distress syndrome in preterminfantrhesus monkeys. PediatrRes 39:715-724
18. Wiswell TE, Smith RM, Katz LB, Mastroianni L, Wong DY, Willms D, Heard S, Wilson M, Hite RD, Anzueto A, Revak SD, Cochrane CG 1999 Bronchopulmonary segmental lavage with Surfaxin (KL(4)-surfactant) for acute respiratory distress syndrome. Am J Respir Crit Care Med 160:1188-1195
19. Babu PB, Chidekel A, Shaffer TH 2005 Hyperoxia-induced changes in human airway epithelial cells: the protective effect of perflubron. Pediatr Crit Care Med 6:188-194
20. Zhu Y, Miller TL, Singhaus CJ, Shaffer TH, Chidekel A 2008 Effects of oxygen concentration and exposure time on cultured human airway epithelial cells. Pediatr Crit Care Med 9:224-229
21. Babu PB, Chidekel A, Shaffer TH 2004 Protein composition of apical surface fluid from the human airway cell line Calu-3: effect of ion transport mediators. Clin Chim Acta 347:81-88
22. Zhang Y, Reenstra WW, Chidekel A 2001 Antibacterial activity of apical surface fluid from the human airway cell line Calu-3: pharmacologic alteration by cortico- steroids and beta(2)-agonists. Am J Respir Cell Mol Biol 25:196-202
23. Coyne CB, Vanhook MK, Gambling TM, Carson JL, Boucher RC, Johnson LG 2002 Regulation of airway tight junctions by proinflammatory cytokines. Mol Biol Cell 13:3218 -3234
24. MillerTL, TouchSM, SinghausCJ, RameshBabuPB, ChidekelA, ShafferTH2006 Expression of matrix metalloproteinases 2, 7 and 9, and their tissue inhibitors 1 and 2, in developing rabbit tracheae. Biol Neonate 89:236-243
25. FosterKA, AveryML, Yazdanian M, Audus KL 2000 Characterization oftheCalu-3 cell line as a tool to screen pulmonary drug delivery. Int J Pharm 208:1-11
26. Borchard G, Cassara ML, Roemele PE, Florea BI, Junginger HE 2002 Transport and local metabolism of budesonide and fluticasone propionate in a human bronchial epithelial cell line (Calu-3). J Pharm Sci 91:1561-1567
27. Cowley EA, Linsdell P 2002 Oxidant stress stimulates anion secretion from the human airway epithelial cell line Calu-3: implications for cystic fibrosis lung disease. J Physiol 43:201-209
28. Bals R, Weiner DJ, Wilson JM 1999 The innate immune system in cystic fibrosis lung disease. J Clin Invest 103:303-307
29. Smith JJ, Travis SM, Greenberg EP, Welsh MJ 1996 Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 85:229-236
30. Travis SM, Conway BA, Zabner J, Smith JJ, Anderson NN, Singh PK, Greenberg EP, Welsh MJ 1999 Activity of abundant antimicrobials of the human airway. Am J Respir Cell Mol Biol 20:872-879
31. Kinniry P, Pick J, Stephens S, Jain D, Solomides CC, Niven R, Segal R, Christ- ofidou-Solomidou M 2006 KL4-surfactant prevents hyperoxic and LPS-induced lung injury in mice. Pediatr Pulmonol 41:916-928
32. Moya FR, Gadzinowski J, Bancalari E, Salinas V, Kopelman B, Bancalari A, Kornacka MK, Merritt TA, Segal R, Schaber CJ, Tsai H, Massaro J, d'Agostino R 2005 A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics 115:1018-1029
33. Moya F, Sinha S, Gadzinowski J, D'Agostino R, Segal R, Guardia C, Mazela J, Liu G 2007 One-year follow-up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials. Pediatrics 119:e1361-e1370
34. Soll RF, Blanco F 2001 Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. Cochrane Database Syst Rev 2:CD000144
35. Krause MF, Wiemann T, Reisner A, Orlowska-Volk M, Kohler H, Ankermann T 2005 Surfactant reduces extravascular lung water and invasion of polymorphonu- clear leukocytes into the lung in a piglet model of airway lavage. Pulm Pharmacol Ther 18:129-139
36. Bhandari V 2002 Developmental differences in the role of interleukins in hyperoxic lung injury in animal models. Front Biosci 7:d1624-d1633
37. Bhandari V, Elias JA 2006 Cytokines in tolerance to hyperoxia-induced injury in the developing and adult lung. Free Radic Biol Med 41:4-18
38. Ikegami M, Whitsett JA, Martis PC, Weaver TE 2005 Reversibility of lung inflammation caused by SP-B deficiency. Am J Physiol Lung Cell Mol Physiol 289:L962-L970
39. Miller TL, Zhu Y, Altman AR, Dysart K, Shaffer TH 2007 Sequential alterations of tracheal mechanical properties in the neonatal lamb: effect of mechanical ventilation. Pediatr Pulmonol 42:141-149
40. Dunsmore SE, Saarialho-Kere UK, Roby JD, Wilson CL, Matrisian LM, Welgus HG, Parks WC 1998 Matrilysin expression and function in airway epithelium. J Clin Invest 102:1321-1331
41. Li Q, Park PW, Wilson CL, Parks WC 2002 Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell 111:635-646